Free tool
FAERS Monitor: Aspruzyo Sprinkle
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216018 or its brand name (Aspruzyo Sprinkle, Ranolazine). Reports on generic versions are filed under their own applications.
Reports
10,544
Serious
9,584
91% of reports
Hospitalization
4,510
Death reported
1,344
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death831
- myocardial infarction650
- chest pain622
- angina pectoris599
- stent placement582
- dyspnoea447
- dizziness438
- fall387
- cerebrovascular accident356
- cardiac disorder311
- off label use302
- nausea292
- malaise287
- drug interaction284
- fatigue277
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 15 |
| 2009 | 23 |
| 2010 | 33 |
| 2011 | 61 |
| 2012 | 115 |
| 2013 | 133 |
| 2014 | 548 |
| 2015 | 1,488 |
| 2016 | 1,180 |
| 2017 | 1,382 |
| 2018 | 1,435 |
| 2019 | 984 |
| 2020 | 331 |
| 2021 | 313 |
| 2022 | 370 |
| 2023 | 426 |
| 2024 | 516 |
| 2025 | 674 |
| 2026 | 507 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,615 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| stent placementSignal | 582 | 155.1 | 142.8 | 82,561 |
| angina pectorisSignal | 599 | 42.6 | 39.3 | 23,796 |
| myocardial infarctionSignal | 650 | 7.5 | 6.9 | 3,644 |
| chest painSignal | 622 | 6.7 | 6.2 | 3,038 |
| cardiac disorderSignal | 311 | 6.6 | 6.0 | 1,489 |
| cerebrovascular accidentSignal | 356 | 4.2 | 3.8 | 869 |
| drug interactionSignal | 284 | 3.6 | 3.2 | 527 |
| fallSignal | 387 | 2.3 | 2.1 | 294 |
| death | 831 | 1.9 | 1.8 | 384 |
| dizziness | 438 | 1.8 | 1.6 | 144 |
| dyspnoea | 447 | 1.6 | 1.4 | 96 |
| malaise | 287 | 1.3 | 1.2 | 21 |
| nausea | 292 | 0.7 | 0.7 | 28 |
| fatigue | 277 | 0.7 | 0.6 | 34 |
| off label use | 302 | 0.7 | 0.6 | 44 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.